Ocular adnexal diffuse large B-cell lymphoma: Local disease correlates with better outcomes

Eye

Volumn 24, Issue 6, 2010, Pages 954-961

  Madge, S N ^a,b   Mccormick, A ^c   Patel, I ^a,b   Hatef, E ^d   Menon, V ^e   Prabhakaran, V C ^a,b   Irion, L ^c   Bonshek, R ^c,f   Honovar, S ^e   Leatherbarrow, B ^c   Esmaeli, B ^d   Selva, D ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b South Australian Institute of Ophthalmology   (Australia)

^c MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e L V PRASAD EYE INSTITUTE   (India)

^f MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Large cell; Lymphoma; Orbit; Survival

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MESNA; METHOTREXATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULAR ADNEXAL DIFFUSE LARGE B CELL LYMPHOMA; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

EID: 77953560081     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.283     Document Type: Article

References (34)

1. Bernadini FP, Bazzan M. Lymphoproliferative disease of the orbit. Curr Opin Ophthalmol 2007; 18: 398-401.
2. Demirci H, Shields CL, Karatza EC, Shields JA. Orbital lymphoproliferative tumors. Analysis of clinical features and systemic involvement in 160 cases. Ophthalmology 2008; 115(9): 1626-1631.
3. Sullivan TJ, Whitehead K, Williamson R, Grimes D, Schlect D, Brown I et al. Lymphoproliferative disease of the ocular adnexa: a clinical and pathologic study with statistical anaylsis of 69 patients. Ophthal Plast Reconstr Surg 2005; 21(3): 177-188.
4. Looi A, Gascoyne RD, Chhanabhai M, Connors JM, Rootman J, White VA. Mantle cell lymphoma in the ocular adnexal region. Ophthalmology 2005; 112: 114-119.
5. Hatef E, Roberts D, McLaughlin P, Pro B, Esmaeli B. Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch Ophthalmol 2007; 125(12): 1663-1667.
6. Demirci H, Shields CL, Shields JA, Honavar SG, Mercado GJ, Tovilla JC. Orbital tumors in the older adult population. Ophthalmology 2002; 109: 243-248.
7. Henderson JW, Campbell RJ, Farrow GM, Garrity JA. Orbital Tumors, 3rd ed. Raven Press: New York, 1994.
8. Rootman J. Diseases of the Orbit: A Multidisciplinary Approach. JB Lipincott: Philadelphia, 1988.
9. Wilson MW, Buggage RR, Grossniklaus HE. Orbital lesions in the southeastern United States. Orbit 1996; 15: 17-24.
10. Kennedy RE. An evaluation of 820 orbital cases. Trans Am Ophthalmol Soc 1984; 82: 134-157.
11. Seregard S, Sahlin S. Panorama of orbital space-occupying lesions. The 24-year experience of a referral centre. Acta Ophthalmol Scand 1999; 77: 91-98.
12. Lazzarino M, Morra E, Rosso R. Clinicopathologic and immunologic characteristics of non-Hodgkin's lymphoma presenting in the orbit. Cancer 1985; 55: 1907-1912.
13. Bardenstein DS. Ocular adnexal lymphoma: classification, clinical disease and molecular biology. Ophthalmol Clin N Am 2005; 18: 187-197.
14. Jaffe ES, Harris NL, Stein H. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues (WHO Classification of Tumours). IARC Press: Lyon, 2001.
15. Harris NL, Jaffe ES, Stein H. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392. (Pubitemid 24273002)
16. Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. Arch Pathol Lab Med 2007; 132: 118-124.
17. Ahmed S, Shahid RK, Sison CP, Fuchs A, Mehrotra B. Orbital lymphomas: a clinicopathologic study of a rare disease. Am J Med Sci 2006; 331(2): 79-83.
18. Sullivan TJ, Grimes D, Bunce I. Monoclonal antibody treatment of orbital lymphoma. Ophthal Plast Reconstr Surg 2004; 20(2): 103-106.
19. Cvetkovic RS, Perry CM. Rituximab. A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006; 66(6): 791-820.
20. Esmaeli B, Ahmadi MA, Manning J, McLaughlin PW, Ginsberg L. Clinical presentation and treatment of secondary orbital lymphoma. Ophthal Plast Reconstr Surg 2002; 18(4): 247-253.
21. McKelvie PA, McNab A, Francis IC, Fox R, O'Day J. Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Exp Ophthalmol 2001; 29: 387-393.
22. Nola M, Lukenda A, Bollman M, Kalauz M, Petrovecki M, Bollmann R. Outcome and prognostic factors in ocular adnexal lymphoma. Croat Med J 2004; 45(3): 328-332.
23. Jenkins C, Rose GE, Bunce C,Wright JE, Cree IA, Plowman N et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol 2000; 84(8): 907-913.
24. Jenkins C, Rose GE, Bunce C, Cree I, Norton A, Plowman PN et al. Clinical features associated with survival of patients with lymphoma of the ocular adnexa. Eye 2003; 17(7): 809-820.
25. Kang SJ, Schmack I, Wojno TH, Grossniklaus HE. Composite lymphoma of the orbit treated with rituximab. Ophthal Plast Reconstr Surg 2002; 20(2): 103-106.
26. Miller T, Unger J, Spier C. Effect of adding rituximab to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse large B-cell lymphoma (SWOG-0014). Blood 2004; 104: a158.
27. Pfreundschuh M, Trumper L, Osterbord A. CHOP-like chemotherapy plus rituximab vs CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma. Lancet Oncol 2006; 7: 379-391.
28. Coiffier B, Lepage E, Briere J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
29. Tanimoto K, Kaneko A, Suzuki S, Sekiguchi N, Maruyama D, Kim SW et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 2006; 17(1): 135-140.
30. Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A et al. Localised mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21(22): 4157-4164.
31. Martinet S, Ozsahin M, Belkac'emi Y, Landmann C, Poortmans P, Oehlere C et al. outcome and prognostic factors in orbital lymphoma: a rare cancer network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Physics 2003; 55(4): 892-898.
32. Raderer M, Vorbeck F, Formanek M, Osterreicher C, Valencak J, Penz M et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 2000; 83(4): 454-457.
33. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005; 237(3): 1038-1045.
34. Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 2007; 34(1): 60-67.